Infrequent p53 mutations in arsenic-related skin lesions

Oncology Research

Volumn 10, Issue 9, 1998, Pages 475-482

  Castrén, Katariina ^b   Ranki, Annamari ^c   Welsh, Judith A ^d   Vähäkangas, Kirsi H ^a  

^a UNIVERSITY OF OULU   (Finland)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^c OULU UNIVERSITY HOSPITAL   (Finland)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Arsenic related skin lesions; Basal cell carcinoma; P53 mutations; Squamous cell carcinoma

Indexed keywords

ARSENIC; PROTEIN P53;

AGED; ARTICLE; BASAL CELL CARCINOMA; CARCINOMA; CHEMICALLY INDUCED DISORDER; GENETICS; HUMAN; KERATOSIS; METABOLISM; MUTATION; RADIATION EXPOSURE; SINGLE STRAND CONFORMATION POLYMORPHISM; SKIN; SKIN TUMOR; SQUAMOUS CELL CARCINOMA; ULTRAVIOLET RADIATION;

AGED; AGED, 80 AND OVER; ARSENIC; CARCINOMA; CARCINOMA, BASAL CELL; CARCINOMA, SQUAMOUS CELL; HUMANS; KERATOSIS; MUTATION; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; SKIN; SKIN NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53; ULTRAVIOLET RAYS;

EID: 0032240949     PISSN: 09650407     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Shannon, R. L.; Strayer, D. S. Arsenic-induced skin toxicity. Hum. Toxicol. 8:99-104; 1989.
2. Farber, E. M. History of the treatment of psoriasis. J. Am. Acad. Dermatol. 27:640-645; 1992.
3. IARC. Some metals and metallic compounds. IARC Monographs on the evaluation of the carcinogenic risk of chemicals to humans, vol. 23. Lyon, France: IARC, WHO; 1980.
4. Rudel, R.; Slayton, T. M.; Beck, B. D. Implications of arsenic gcnotoxicity for dose response of carcinogenic effects. Regul. Toxicol. Pharmacol. 23:87-105; 1996.
5. 3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR α/PML proteins. Blood 88:1052-1061; 1996.
6. Kastan, M. B.; Onyekwere, O.; Sidransky, D.; Vogelstein, B.; Craig, R. W. Participation of p53 protein in the cellular response to DNA damage. Cancer Res. 51:6304-6311; 1991.
7. Rämet, M.; Castrén, K.; Järvinen, K.; Pekkala, K.; Turpeenniemi-Hujanen, T.; Soini, Y.; Pääkkö, P.; Vähäkangas, K. p53 protein expression is correlated with benzo(a)pyrene-DNA adducts in carcinoma cell lines. Carcinogenesis 16:2117-2124; 1995.
8. Kubo, Y.; Urano, Y.; Yoshimoto, K.; Iwahana, H.; Fukuhara, K.; Arase, S.; Itakura, M. p53 gene mutations in human skin cancers and precancerous lesions: Comparison with immunohistochemical analysis. J. Invest. Dermatol. 102:440-444; 1994.
9. McNutt, N. S.; Saenz-Santamaria, C.; Volkenandt, M.; Shea, C. R.; Albino, A. P. Abnormalities of p53 protein expression in cutaneous disorders. Arch. Dermatol. 130:225-232; 1994.
10. Castrén, K.; Vähäkangas, K.; Heikkinen, E.; Ranki, A. Absence of p53 mutations in benign and prcmalignant male genital lesions with overexpressed p53 protein. Int. J. Cancer 77:674-678; 1998.
11. Gloster, H. M.; Brodland, D. G. The epidemiology of skin cancer. Dermatol. Surg. 22:217-226; 1996.
12. Greenblatt, M. S.; Bennett, W. P.; Hollstein, M.; Harris, C. C. Mutations in the p53 tumor suppressor gene: Clues to cancer etiology and molecular pathogenesis. Cancer Res. 54:4855-4878; 1994.
13. Brash, D. E.; Rudolph J. A.; Simon, J. A.; Lin, A.; McKenna, G. J.; Baden, H. P.; Halperin, A. J.; Ponten, J. A role for sunlight in skin cancer: UV-induced p53 mutations in squamous cell carcinoma. Proc. Natl. Acad. Sci. USA 88:10124-10128; 1991.
14. zur Hausen, H. Papillomavirus infections-a major cause of human cancers. Biochim. Biophys. Acta 1288:F55-78; 1996.
15. Lehman, T. A.; Bennett, W. P.; Metcalf, R. A.; Welsh, J. A.; Ecker, J.; Modali, R. V.; Ullrich, S.; Romano, J. W.; Appella, E.; Testa, J. R.; Gerwin, B. I.; Harris, C. C. p53 mutations, ras mutations, and p53-heat shock 70 protein complexes in human lung carcinoma cell lines. Cancer Res. 51:4090-4096; 1991.
16. Welsh, J. A.; Castrén, K.; Vähäkangas, K. H. Single strand conformation polymorphism analysis to detect p53 mutations: Characteration and development of controls. Clin. Chem. 43:2251-2255; 1997.
17. Vähäkangas, K. H.; Samet, J. M.; Metcalf, R. A.; Welsh, J. A.; Bennett, W. P.; Lane, D. P.; Harris, C. C. Mutations of p53 and ras genes in radon-associated lung cancer from uranium miners. Lancet 339:576-580; 1992.
18. Ranki, A.; Lassus, J.; Niemi, K. M. Relation of p53 tumor suppressor protein expression to human papillomavirus (HPV) DNA and to cellular atypia in male genital warts and premalignant lesions. Acta Derm. Venereol. 75:180-186; 1995.
19. Midgley, C. A.; Fisher, C. J.; Bartek, J.; Vojtesek, B.; Lane, D.; Barnes, D. M. Analysis of p53 expression in human tumors: An antibody raised against human p53 expressed in E. coll. J. Cell Sci. 101:183-189; 1992.
20. Hsieh, L.-L.; Chen, H.-J.; Hsieh, J.-T.; Jee, S.-H.; Chen, G.-S.; Chen, C.-J. Arsenic-related Bowen's disease and paraquat-related skin cancerous lesions show no detectable ras and p53 gene alterations. Cancer Lett. 86:59-65; 1994.
21. Shibata, A.; Ohneseit, P. F.; Tsai, Y. C.; Spruck, C. H., III; Nichols, P. W.; Chiang, H.-S.; Lai, M.-K.; Jones, P. A. Mutational spectrum in the p53 gene in bladder tumors from the endemic area of black foot disease in Taiwan. Carcinogenesis 15:1085-1087; 1994.
22. Nishigori, C.; Kulthanan, K.; Kullavanijaya, P.; Yu, H.-S.; Imamura, S. Alterations in p53 gene on arsenic-induced skin cancers - possible role of oxygen radicals. J. Invest. Dermatol. 110: 522; 1998.
23. Matsumura, Y.; Nishigori, C.; Yagi, T.; Imamura, S.; Takebe, H. Characterization of p53 gene mutations in basal-cell carcinomas: Comparison between sun-exposed and less-exposed skin areas. Int. J. Cancer 65:778-780; 1996.
24. Cheng, J.; Haas, M. Sensitivity of detection of heterozygous point mutations in p53 cDNAs by direct PCR sequencing. PCR Methods Appl. 1:199-201; 1992.
25. Peng, H.; Du, M.; Ji, J.; Isaacson, P. G.; Pan, L. High-resolution SSCP analysis using polyacrylamide agarose composite gel and a backround-free silver staining method. Biotechniques 19:411-414; 1995.
26. Wu, J. K.; Ye, Z.; Darras, B. T. Sensitivity of single-strand conformation polymorphism (SSCP) analysis in detecting p53 point mutations in tumors with mixed cell populations. Am. J. Hum. Gen. 52:1273-1275; 1993.
27. Kuo, T. T.; Hu, S.; Lo, S. K.; Chan, H. L. p53 expression and proliferative activity in Bowen's disease with or without chronic arsenic exposure. Hum. Pathol. 28:786-790; 1997.
28. Hainaut, P.; Vähäkangas, K. p53 as a sensor of carcinogenic exposures: Mechanisms of p53 protein induction and lessons from p53 gene mutations. Pathol. Biol. (Paris) 45:833-844; 1997.
29. Hall, P. A.; McKee, P. H.; Menage, H. du P.; Dover, R.; Lane D. P. High levels of p53 protein in UV-irradiated normal human skin. Oncogene 8:203-207; 1993.
30. Soini, Y.; Kamel, D.; Pääkkö, P.; Lchto, V.-P.; Oikarinen, A.; Vähäkangas, K. Aberrant accumulation of p53 associates with Ki67 and mitotic count in benign skin lesions. Br. J. Dermatol. 131:514-520; 1994.